Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $758

Benzinga Newsdesk www.benzinga.com Positive 71.1%

Neg 0% Neu 0% Pos 71.1%

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $730 to $758.